What are the latest funding news in the biotechnology market? (March 2026)
Download our beautiful pitch about the biotechnology market
In our biotechnology market deck, you will find everything you need to understand the market
The biotechnology market saw a strong wave of funding activity in early 2026, with 12 biopharma and therapeutics companies collectively raising over $1.2 billion between late January and late February.
Deals spanned the full development spectrum, from preclinical RNA medicine platforms to a fully FDA-approved presbyopia eye drop heading to commercial launch.
Neurology, immunology, and cardiology were among the most active therapeutic focus areas, with several companies attracting large syndicates of crossover and institutional investors.
And if you want to better understand this new industry, you can download our pitch covering the biotechnology market.
Insights
- The 12 deals announced between January 27 and February 27, 2026 totaled over $1.29 billion, with an average round size of roughly $108M -- reflecting sustained appetite from crossover and institutional investors for biopharma R&D despite macro uncertainty.
- Janus Henderson Investors appeared as an investor in at least four separate rounds (Korsana, ILiAD, Tenpoint, TRexBio), making them one of the most active crossover funds in biotech funding during this period.
- RA Capital Management co-led or participated in three deals (Slate Medicines, ILiAD Biotechnologies, Angitia Biopharmaceuticals), reinforcing its position as a dominant force in late-stage biotech venture financing.
- Sanofi's venture arm appeared in three rounds (Altesa, QuantX, Korsana), suggesting the pharma giant is actively seeding early-stage assets across immunology, antiviral, and CNS as part of a broader pipeline-building strategy in the biotechnology market.
- Four of the 12 companies were at preclinical or IND-enabling stage yet collectively raised over $535M, signaling that investors remain willing to back platform bets very early in the biotechnology development cycle.
- The lone commercial-stage deal -- Tenpoint Therapeutics raising $85M to launch its FDA-approved presbyopia eye drop -- also secured a parallel $150M debt facility, showing that biotech commercialization increasingly relies on blended equity and debt structures.
- Two companies in the batch (BreezeBio and Angitia Biopharmaceuticals) had investors from both Korean and U.S. funds, pointing to growing cross-Pacific capital flows into the biotechnology therapeutics market.
- Migraine, Alzheimer's, COPD, and pertussis vaccines all attracted fresh capital, suggesting a renewed emphasis on diseases with large unmet need where prior clinical validation exists but differentiated mechanisms remain competitive.
In our biotechnology market deck, we have collected signals proving this market is hot right now
Summary table of the latest funding deals in the biotechnology market as of March 2026
We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes.
We include biopharma R&D and therapeutics (including biologics, cell/gene therapies, and vaccines), molecular diagnostics, and core life-science research tools and reagents used to generate and analyze biological data.
We exclude routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture/industrial bioapplications unless they are explicitly in scope for the analysis.
You can also read our detailed analysis to understand how funding activity in the biotechnology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the biotechnology market (we update this list every quarter).
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Atrium Therapeutics | Feb 27, 2026 | $270M | Launch Financing | Therapeutics (RNA & Rare Cardiomyopathies) |
| BreezeBio | Feb 25, 2026 | $60M | Series B | Therapeutics (Genetic Medicine Delivery) |
| Slate Medicines | Feb 24, 2026 | $130M | Series A | Therapeutics (Neurology & mAb) |
| Altesa BioSciences | Feb 19, 2026 | $75M | Series B | Therapeutics (Antiviral & Respiratory) |
| Korsana Biosciences | Feb 18, 2026 | $175M | Seed / Series A | Therapeutics (Neurology & CNS Biologics) |
| ILiAD Biotechnologies | Feb 10, 2026 | $115M | Series B | Vaccines (Pertussis) |
| QuantX Biosciences | Feb 9, 2026 | $85M | Series B | Therapeutics (Computational Drug Discovery & Immunology) |
| Angitia Biopharmaceuticals | Feb 5, 2026 | $130M | Series D | Therapeutics (Biologics & Musculoskeletal) |
| Third Arc Bio | Feb 4, 2026 | $52M | Series A Extension | Therapeutics (Engineered Antibodies & Oncology) |
| Tenpoint Therapeutics | Jan 29, 2026 | $85M | Series B | Therapeutics (Ophthalmology & Commercialization) |
| Breakthru Medicine | Jan 29, 2026 | $60M | Series A | Therapeutics (Oncology R&D Platform) |
| TRexBio | Jan 27, 2026 | $50M | Financing | Therapeutics (Immunology & Treg Biology) |
All the latest funding deals in the biotechnology market as of March 2026
Atrium Therapeutics launched with $270 million in February 2026 to advance RNA medicines targeting rare genetic cardiomyopathies.
When was it?
The deal was announced on February 27, 2026.
Who are they?
Atrium Therapeutics is a San Diego-based biotech developing heart-targeted siRNA medicines for rare genetic cardiomyopathies, with two programs in IND-enabling studies.
Geographical focus?
Atrium Therapeutics has a global rare-disease focus, headquartered in San Diego with no region-specific commercial strategy disclosed at this stage.
Why do we include them in the biotechnology market?
Atrium Therapeutics fits squarely in the biopharma R&D and therapeutics segment of the biotechnology market, applying RNA interference technology to develop novel cardiac drugs.
What is the company stage?
Atrium Therapeutics is at the preclinical and IND-enabling stage, with Phase 1 trials planned for its lead siRNA programs.
How much did they raise?
Atrium Therapeutics raised approximately $270 million in launch financing disclosed at the time of the company's founding announcement.
What round is it?
This was a launch financing round, not a traditional venture series, as Atrium Therapeutics emerged as a new standalone company.
Why did they raise?
Atrium Therapeutics raised this capital to fund IND-enabling work for two siRNA programs and progress them into Phase 1 clinical trials.
In our biotechnology market deck, we help you understand how the market is structured
BreezeBio closed a $60 million Series B in February 2026 to advance its non-viral nanoparticle platform for immune tolerance.
When was it?
The deal was announced on February 25, 2026.
Who are they?
BreezeBio (formerly GenEdit) is a biotech company using its NanoGalaxy non-viral nanoparticle platform to deliver genetic medicines that restore immune tolerance, starting with Type 1 diabetes.
Geographical focus?
BreezeBio is a US-based company with no stated regional focus, pursuing global indications in immune-mediated diseases.
Why do we include them in the biotechnology market?
BreezeBio belongs in the biotechnology market under the biopharma R&D and therapeutics segment, specifically genetic medicine delivery using engineered nanoparticles and mRNA payloads.
What is the company stage?
BreezeBio is at the IND-enabling stage, with its lead program BRZ-101 advancing toward first clinical studies.
How much did they raise?
BreezeBio raised $60 million in this Series B round.
What round is it?
This was a Series B round, co-led by Yuanta Investment and DSC Investment along with additional new and existing investors.
Why did they raise?
BreezeBio raised the capital to push BRZ-101 through IND-enabling studies and continue expanding its NanoGalaxy delivery platform.
Slate Medicines raised $130 million in a Series A in February 2026 to develop an anti-PACAP antibody for migraine prevention.
When was it?
The deal was announced on February 24, 2026.
Who are they?
Slate Medicines is a North Carolina-based biotech developing subcutaneous anti-PACAP monoclonal antibody therapies designed for at-home use in preventing migraine and related headache disorders.
Geographical focus?
Slate Medicines has no specific regional focus, though the company licensed its lead asset from DartsBio in China and targets the global migraine treatment market.
Why do we include them in the biotechnology market?
Slate Medicines fits the biotechnology market under biopharma R&D and therapeutics, developing a biologic monoclonal antibody against a clinically validated neurological target (PACAP).
What is the company stage?
Slate Medicines is at the preclinical stage, with Phase 1 trials for its lead candidate SLTE-1009 planned for mid-2026.
How much did they raise?
Slate Medicines raised $130 million in this round.
What round is it?
This was a Series A, co-led by RA Capital Management, Forbion, and Foresite Capital alongside one undisclosed biotech investor.
Why did they raise?
Slate Medicines raised this funding to finance its Phase 1 program for SLTE-1009 and build out an undisclosed broader pipeline.
In our biotechnology market deck, we identify repeatable patterns you can use if you’re building in this market
Altesa BioSciences closed an oversubscribed $75 million Series B in February 2026 to run a pivotal Phase 2b trial in COPD.
When was it?
The deal was announced on February 19, 2026.
Who are they?
Altesa BioSciences is a clinical-stage biotech developing vapendavir, an oral antiviral targeting rhinovirus to prevent dangerous lung exacerbations in patients with COPD.
Geographical focus?
Altesa BioSciences has a U.S. and U.K. focus for its upcoming CARDINAL Phase 2b trial, enrolling 900 COPD patients across both markets.
Why do we include them in the biotechnology market?
Altesa BioSciences belongs in the biotechnology market under biopharma R&D and therapeutics, specifically antiviral drug development enabled by modern translational and clinical science.
What is the company stage?
Altesa BioSciences is at the clinical stage, with a Phase 2b trial for vapendavir in COPD about to launch.
How much did they raise?
Altesa BioSciences raised $75 million in this oversubscribed round.
What round is it?
This was a Series B, led by Forbion with participation from Sanofi and existing investors including Medicxi, Pitango, and Atlantic Partners.
Why did they raise?
Altesa BioSciences raised this capital to fund the CARDINAL Phase 2b study and build toward late-stage development of vapendavir.
Korsana Biosciences launched with $175 million in February 2026 to develop a blood-brain barrier-crossing antibody for Alzheimer's disease.
When was it?
The deal was announced on February 18, 2026.
Who are they?
Korsana Biosciences is a biotech company engineering antibodies with proprietary shuttle technology designed to cross the blood-brain barrier, with a lead anti-amyloid antibody (KRSA-028) for Alzheimer's disease.
Geographical focus?
Korsana Biosciences has no specific regional focus and is targeting the global Alzheimer's disease market, where unmet need remains enormous.
Why do we include them in the biotechnology market?
Korsana Biosciences fits the biotechnology market under biopharma R&D and therapeutics, specifically CNS biologics using advanced protein engineering to enable brain-targeted drug delivery.
What is the company stage?
Korsana Biosciences is at the preclinical stage, with first-in-human trials planned for around 2027.
How much did they raise?
Korsana Biosciences raised $175 million in this round.
What round is it?
This was a Seed/Series A round backed by a large syndicate including Fairmount, Venrock Healthcare Capital Partners, Wellington Management, J.P. Morgan Life Sciences Private Capital, Sanofi Ventures, and Foresite Capital among others.
Why did they raise?
Korsana Biosciences raised this funding to build out the company and advance KRSA-028 into first-in-human clinical studies.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
ILiAD Biotechnologies raised $115 million in a Series B in February 2026 to advance its next-generation nasal pertussis vaccine.
When was it?
The deal was announced on February 10, 2026.
Who are they?
ILiAD Biotechnologies is a clinical-stage biotech developing BPZE1, a next-generation nasally administered pertussis (whooping cough) vaccine designed to improve protection and potentially reduce disease transmission.
Geographical focus?
ILiAD Biotechnologies is addressing a public-health need in both the U.S. and Europe, where pertussis case numbers have been rising significantly.
Why do we include them in the biotechnology market?
ILiAD Biotechnologies belongs in the biotechnology market under the vaccines segment, applying modern clinical vaccine development science to a disease with growing public health urgency.
What is the company stage?
ILiAD Biotechnologies is at the clinical stage, with multiple human studies completed and a prior Phase 2b trial reported.
How much did they raise?
ILiAD Biotechnologies raised $115 million in this oversubscribed round.
What round is it?
This was a Series B led by RA Capital Management, with new investors Janus Henderson Investors and BNP Paribas Asset Management Alts participating alongside existing shareholders.
Why did they raise?
ILiAD Biotechnologies raised this capital to accelerate the development of BPZE1 as whooping cough cases continue to surge globally.
QuantX Biosciences closed an $85 million Series B in February 2026 to develop oral small-molecule immunology drugs using computational modeling.
When was it?
The deal was announced on February 9, 2026.
Who are they?
QuantX Biosciences is a drug discovery company combining computational modeling and high-performance computing to design oral small-molecule inhibitors targeting STAT6 and IL-17 for immune-mediated diseases.
Geographical focus?
QuantX Biosciences has both U.S. and China footprints, with operations noted in Princeton and Shanghai.
Why do we include them in the biotechnology market?
QuantX Biosciences fits the biotechnology market under biopharma R&D and therapeutics, using computational biology to discover and develop next-generation small-molecule drugs for immunology.
What is the company stage?
QuantX Biosciences is at the IND-enabling and preclinical stage, using the financing to support clinical development of its lead immunology candidates.
How much did they raise?
QuantX Biosciences raised $85 million in this oversubscribed round.
What round is it?
This was a Series B co-led by LAV and Sanofi Ventures, with additional participation from Hongshan and existing investors.
Why did they raise?
QuantX Biosciences raised this capital to fund clinical development of its STAT6 and IL-17 oral inhibitors and continue expanding its computational drug discovery engine.
In our biotechnology market deck, we will give you useful market maps and grids
Angitia Biopharmaceuticals raised $130 million in a Series D in February 2026 to advance bispecific biologics for bone diseases.
When was it?
The deal was announced on February 5, 2026.
Who are they?
Angitia Biopharmaceuticals is a clinical-stage biotech developing bispecific biologics that target bone-building pathways (including sclerostin and DKK1) for conditions such as osteoporosis, osteogenesis imperfecta, and spinal fusion.
Geographical focus?
Angitia Biopharmaceuticals has no specific regional focus, targeting global musculoskeletal disease markets with significant unmet medical need.
Why do we include them in the biotechnology market?
Angitia Biopharmaceuticals belongs in the biotechnology market under biopharma R&D and therapeutics, developing innovative biologic medicines for serious skeletal diseases.
What is the company stage?
Angitia Biopharmaceuticals is at the clinical stage, with multiple Phase 2 and Phase 3 programs ongoing across its three bone disease asset pipeline.
How much did they raise?
Angitia Biopharmaceuticals raised $130 million in this round.
What round is it?
This was a Series D co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with new investors including RA Capital, Wellington, Logos Capital, BVF Partners, and Bain Capital Life Sciences among others.
Why did they raise?
Angitia Biopharmaceuticals raised this capital to push its three bone disease programs deeper into the clinic and compete against established players in the osteoporosis space.
Third Arc Bio raised $52 million in a Series A extension in February 2026 to expand its multifunctional antibody pipeline in oncology and immunology.
When was it?
The deal was announced on February 4, 2026.
Who are they?
Third Arc Bio is a clinical-stage biotech developing multifunctional antibodies engineered to create improved immune synapses for both oncology and immunology and inflammation indications.
Geographical focus?
Third Arc Bio has no specific regional focus and is developing its antibody platform for global oncology and immunology markets.
Why do we include them in the biotechnology market?
Third Arc Bio fits the biotechnology market under biopharma R&D and therapeutics, engineering novel antibody formats to address cancer and inflammatory disease.
What is the company stage?
Third Arc Bio is at the clinical stage, with its lead program actively in Phase 1 trials.
How much did they raise?
Third Arc Bio raised $52 million in this extension round.
What round is it?
This was a Series A extension led by Andreessen Horowitz (a16z) and Omega Funds, with a broad syndicate also including Goldman Sachs Alternatives, AbbVie Ventures, T. Rowe Price, Hillhouse, and BVF among others.
Why did they raise?
Third Arc Bio raised this capital to expand its oncology and immunology portfolio and continue advancing the multifunctional antibody engineering platform.
In our biotechnology market deck, we answer all the common questions from investors and entrepreneurs
Tenpoint Therapeutics closed an $85 million Series B in January 2026 to fund the U.S. commercial launch of its FDA-approved presbyopia eye drop.
When was it?
The deal was announced on January 29, 2026.
Who are they?
Tenpoint Therapeutics is a commercial-stage ophthalmology company launching YUVEZZI, an FDA-approved prescription eye drop that corrects presbyopia (age-related near-vision loss) with a combination drug approach.
Geographical focus?
Tenpoint Therapeutics is focused on the U.S. market, where YUVEZZI's commercial launch is planned for Q2 2026.
Why do we include them in the biotechnology market?
Tenpoint Therapeutics belongs in the biotechnology market under biopharma R&D and therapeutics, as YUVEZZI is a novel pharmacological therapy for a widely prevalent eye condition enabled by modern drug development science.
What is the company stage?
Tenpoint Therapeutics is at the commercial stage, with YUVEZZI having received FDA approval and the company now building out its salesforce and launch infrastructure.
How much did they raise?
Tenpoint Therapeutics raised $85 million in equity through this Series B, alongside a separate $150 million debt facility from Hercules Capital.
What round is it?
This was a Series B led by Janus Henderson, EQT Nexus, Hillhouse, and British Business Bank, with existing investors including EQT Life Sciences, Sofinnova Partners, F-Prime, and Eight Roads also participating.
Why did they raise?
Tenpoint Therapeutics raised this capital to fund its U.S. launch, build its commercial salesforce, and support the growth trajectory of YUVEZZI post-approval.
Breakthru Medicine emerged from stealth with a $60 million Series A in January 2026 to build an oncology drug development platform.
When was it?
The deal was announced on January 29, 2026.
Who are they?
Breakthru Medicine is an oncology-focused biotech emerging from stealth that is building a platform using multiple modalities, including molecular glues and ADC payloads, to develop treatments for aggressive solid tumors.
Geographical focus?
Breakthru Medicine has no specific regional focus and is targeting global oncology markets with its multi-modality platform approach.
Why do we include them in the biotechnology market?
Breakthru Medicine fits the biotechnology market under biopharma R&D and therapeutics, applying modern drug discovery modalities to the development of novel cancer treatments.
What is the company stage?
Breakthru Medicine is at the early preclinical stage, having just emerged from stealth with this Series A to fund its platform build and initial oncology programs.
How much did they raise?
Breakthru Medicine raised $60 million in this round.
What round is it?
This was a Series A, with board and investor figures including Dave Morehead, Fred Eshelman of Eshelman Ventures, and Mark Gergen involved in backing the company.
Why did they raise?
Breakthru Medicine raised this capital to fund its early oncology programs across multiple drug discovery modalities and work toward clinical entry.
In our biotechnology market deck, we have designed useful charts to give you full market clarity
TRexBio closed a $50 million oversubscribed financing in January 2026 to advance its clinical-stage Treg immunology pipeline.
When was it?
The deal was announced on January 27, 2026.
Who are they?
TRexBio is a clinical-stage immunology company decoding tissue-resident regulatory T cell (Treg) biology to develop precision immunoregulatory medicines, with its lead TNFR2 agonist TRB-061 currently in Phase 1a/b trials.
Geographical focus?
TRexBio is a U.S.-based company with no stated regional focus, developing medicines for systemic autoimmune and inflammatory diseases.
Why do we include them in the biotechnology market?
TRexBio fits the biotechnology market under biopharma R&D and therapeutics, applying computational biology and Treg science to discover and develop differentiated immunology drugs.
What is the company stage?
TRexBio is at the clinical stage, with TRB-061 in Phase 1a/b trials and additional preclinical candidates advancing toward the clinic.
How much did they raise?
TRexBio raised $50 million in this oversubscribed round.
What round is it?
The round type was not specified, but new investors Janus Henderson Investors, Balyasny Asset Management, and Affinity Asset Advisors joined existing backers including Eli Lilly, JJDC, Pfizer Ventures, Polaris, and SV Health.
Why did they raise?
TRexBio raised this capital to advance TRB-061 through Phase 1 and move its next two pipeline candidates, TRB-071 and TRB-081, toward clinical entry.
Related blog posts
- What is the latest update in the biotechnology market?
- What are the latest news in the biotechnology market?
- What is the real market size of the biotechnology market?
- Evolution of the funding activity in the biotechnology market
- What are the fundraising trends in the biotechnology market?
